{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T02:30:55Z","timestamp":1791599455495,"version":"4.3.4"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.bmcl.2024.129612","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T11:49:57Z","timestamp":1704714597000},"page":"129612","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Design, synthesis, and evaluation of dual EGFR\/AURKB inhibitors as anticancer agents for non-small cell lung cancer"],"prefix":"10.1016","volume":"100","author":[{"given":"Sonali","family":"Kurup","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayna","family":"Gesinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlin","family":"Assaad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aidan","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2024.129612_b0005","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.bmcl.2024.129612_b0010","first-page":"2958","article-title":"A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor","volume":"7","author":"Ciardiello","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmcl.2024.129612_b0015","unstructured":"http:\/\/www.cancer.org\/cancer\/lungcancer\/ Last accessed: Dec 16, 2023."},{"key":"10.1016\/j.bmcl.2024.129612_b0020","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc969","article-title":"Targeting RAS signalling pathways in cancer therapy","volume":"3","author":"Downward","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bmcl.2024.129612_b0025","doi-asserted-by":"crossref","first-page":"800","DOI":"10.3389\/fonc.2019.00800","article-title":"Rethink of EGFR in cancer with its kinase independent function on board","volume":"9","author":"Thomas","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.bmcl.2024.129612_b0030","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol Cancer"},{"key":"10.1016\/j.bmcl.2024.129612_b0035","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12943-018-0804-2","article-title":"Kinase-targeted cancer therapies: progress, challenges and future directions","volume":"17","author":"Bhullar","year":"2018","journal-title":"Mol Cancer"},{"key":"10.1016\/j.bmcl.2024.129612_b0040","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx702","article-title":"Overview of current systemic management of EGFR-mutant NSCLC","volume":"29","author":"Hsu","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bmcl.2024.129612_b0045","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1073\/pnas.0709662105","article-title":"The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP","volume":"105","author":"Yun","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bmcl.2024.129612_b0050","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1021\/acs.jmedchem.7b01310","article-title":"Recent progress of small-molecule epidermal growth factor receptor (EGFR) inhibitors against C797S resistance in non-small-cell lung cancer","volume":"61","author":"Chen","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2024.129612_b0055","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1158\/1078-0432.CCR-15-0560","article-title":"The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies","volume":"21","author":"Niederst","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmcl.2024.129612_b0060","first-page":"230","article-title":"Resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer","volume":"1","author":"Van Der Steen","year":"2018","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.bmcl.2024.129612_b0065","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1007\/s00432-021-03647-x","article-title":"A bug in the resistance to EGFR inhibitors: is there a role for Mycoplasma and cytidine deaminase in reducing the activity of osimertinib in lung cancer patients?","volume":"147","author":"Leonetti","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.bmcl.2024.129612_b0070","doi-asserted-by":"crossref","unstructured":"EGFR, KRAS and BRAF mutations are mutually exclusive. Cancer Genome Atlas Research Network: Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014; 511, 543.","DOI":"10.1038\/nature13385"},{"key":"10.1016\/j.bmcl.2024.129612_b0075","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1021\/acs.biochem.8b00376","article-title":"It takes two to target: A study in KRAS dimerization","volume":"57","author":"Nabet","year":"2018","journal-title":"Biochemistry"},{"key":"10.1016\/j.bmcl.2024.129612_b0080","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/1759-7714.12266","article-title":"Clinical outcome of epidermal growth factor receptor-tyrosine kinase inhibitors therapy for patients with overlapping kirsten rat sarcoma 2 viral oncogene homolog and epidermal growth factor receptor gene mutations","volume":"7","author":"Zhang","year":"2016","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.bmcl.2024.129612_b0085","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1021\/jm8012129","article-title":"Discovery and development of AURK inhibitors as anticancer agents","volume":"52","author":"Pollard","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2024.129612_b0090","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.3892\/ol.2017.6012","article-title":"AURKA mRNA expression is an independent predictor of poor prognosis in patients with non-small cell lung cancer","volume":"13","author":"Al-Khafaji","year":"2017","journal-title":"Oncol Lett"},{"key":"10.1016\/j.bmcl.2024.129612_b0095","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41591-018-0264-7","article-title":"AURK A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer","volume":"25","author":"Shah","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.bmcl.2024.129612_b0100","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.ccell.2021.07.006","article-title":"Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis","volume":"39","author":"Tanaka","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bmcl.2024.129612_b0105","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1038\/s41467-019-09734-5","article-title":"AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy","volume":"10","author":"Bertran-Alamillo","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmcl.2024.129612_b0110","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12943-016-0494-6","article-title":"AURK targeting in lung cancer reduces KRAS-induced transformation","volume":"15","author":"Dos Santos","year":"2016","journal-title":"Mol Cancer"},{"key":"10.1016\/j.bmcl.2024.129612_b0115","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1126\/science.1254721","article-title":"Patient-derived models of acquired resistance can identify effective drug combinations for cancer","volume":"346","author":"Crystal","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.bmcl.2024.129612_b0120","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrc2787","article-title":"Targeting the cancer kinome through polypharmacology","volume":"10","author":"Knight","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bmcl.2024.129612_b0125","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.1021\/jm800475y","article-title":"Knowledge based prediction of ligand binding modes and rational inhibitor design for kinase drug discovery","volume":"51","author":"Ghose","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2024.129612_b0130","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.1371\/journal.pbio.0040144","article-title":"A Src-like inactive conformation in the abl tyrosine kinase domain","volume":"5","author":"Levinson","year":"2006","journal-title":"PLoS Biol"},{"key":"10.1016\/j.bmcl.2024.129612_b0135","doi-asserted-by":"crossref","first-page":"4931","DOI":"10.1158\/0008-5472.CAN-03-3681","article-title":"AEE788: a dual family epidermal growth factor receptor\/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity","volume":"64","author":"Traxler","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmcl.2024.129612_b0140","doi-asserted-by":"crossref","first-page":"6652","DOI":"10.1158\/0008-5472.CAN-04-1168","article-title":"A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells","volume":"64","author":"Wood","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmcl.2024.129612_b0145","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nature17960","article-title":"Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors","volume":"534","author":"Jia","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2024.129612_b0150","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1021\/cb100053q","article-title":"Drug-resistant aurora A mutants for cellular target validation of the small molecule kinase inhibitors MLN8054 and MLN8237","volume":"5","author":"Sloane","year":"2010","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.bmcl.2024.129612_b0155","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1158\/2159-8290.CD-18-0469","article-title":"Aurora A kinase inhibition is synthetic lethal with loss of the RB1 tumor suppressor gene","volume":"9","author":"Gong","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bmcl.2024.129612_b0160","doi-asserted-by":"crossref","unstructured":"Bavetsias, Sessa, F, Villa, F. Structure of Aurora B-Incenp in complex with barasertib reveals a potential transinhibitory mechanism. Acta Crystallogr, Sect F 2014, 70, 294.","DOI":"10.1107\/S2053230X14002118"},{"key":"10.1016\/j.bmcl.2024.129612_b0165","doi-asserted-by":"crossref","first-page":"23937","DOI":"10.18632\/oncotarget.14893","article-title":"AURKs: novel therapy targets in cancers","volume":"8","author":"Tang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bmcl.2024.129612_b0170","unstructured":"Molecular Operating Environment (MOE 2022.10), Chemical Computing Group, Inc, 1255 University St., Suite 1600, Quebec, Canada, H3B3X3."},{"key":"10.1016\/j.bmcl.2024.129612_b0175","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1080\/14756366.2017.1376666","article-title":"Design, synthesis and biological activity of N(4)-phenylsubstituted-7H-pyrrolo[2,3-d]pyrimidin-4-amines as dual inhibitors of AURKA and epidermal growth factor receptor kinase","volume":"33","author":"Kurup","year":"2018","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10.1016\/j.bmcl.2024.129612_b0180","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1089\/adt.2009.0222","volume":"7","author":"Zegzouti","year":"2009","journal-title":"Assay Drug Dev Technol"},{"key":"10.1016\/j.bmcl.2024.129612_b0185","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/1087057108326663","article-title":"High-throughput biochemical kinase selectivity assays: panel development and screening applications","volume":"14","author":"Card","year":"2009","journal-title":"J Biomol Screen"},{"key":"10.1016\/j.bmcl.2024.129612_b0190","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1021\/acsmedchemlett.9b00065","article-title":"Identification of RIPK3 Type II Inhibitors Using High-Throughput Mechanistic Studies in Hit Triage","volume":"11","author":"Hart","year":"2020","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmcl.2024.129612_b0195","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/CCO.0b013e328011a25f","article-title":"Ba\/F3 cells and their use in kinase drug discovery","volume":"19","author":"Warmuth","year":"2007","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.bmcl.2024.129612_b0200","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/cas.15263","article-title":"Utility of the Ba\/F3 cell system for exploring on-target mechanisms of resistance to targeted therapies for lung cancer","volume":"113","author":"Koga","year":"2022","journal-title":"Cancer Sci"},{"key":"10.1016\/j.bmcl.2024.129612_b0205","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/978-1-0716-3397-7_8","article-title":"NanoBRET live-cell kinase selectivity profiling adapted for high-throughput screening","volume":"2706","author":"Nieman","year":"2023","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.bmcl.2024.129612_b0210","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/nchembio.1337","article-title":"Metrics other than potency reveal systematic variation in responses to cancer drugs","volume":"9","author":"Fallahi-Sichani","year":"2013","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.bmcl.2024.129612_b0215","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nature11003","article-title":"The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"Barretina","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2024.129612_b0220","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nrc1951","article-title":"The NCI60 human tumor cell line anticancer drug screen","volume":"6","author":"Shoemaker","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bmcl.2024.129612_b0225","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nbt1358","article-title":"A quantitative analysis of kinase inhibitor selectivity","volume":"25","author":"Karaman","year":"2008","journal-title":"Nat. Biotechnology"},{"key":"10.1016\/j.bmcl.2024.129612_b0230","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1747-0285.2009.00832.x","article-title":"On the origins of enzyme inhibitor selectivity and promiscuity: a case study of protein kinase binding to staurosporine","volume":"74","author":"Tanramluk","year":"2009","journal-title":"Chem Biol Drug Des"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X24000143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X24000143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:49:32Z","timestamp":1760773772000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X24000143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":46,"alternative-id":["S0960894X24000143"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2024.129612","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and evaluation of dual EGFR\/AURKB inhibitors as anticancer agents for non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2024.129612","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"129612"}}